On Wednesday, Juno Therapeutics Inc (NASDAQ:JUNO)’s shares declined -1.75% to $38.24.
Juno Therapeutics, Inc. (JUNO) declared that it will webcast its presentation at the 2015 Morgan Stanley Global Healthcare Conference at 4:15 p.m. ET on Wednesday, September 16, 2015. The presentation will feature a business overview and update by Steve Harr, Juno’s Chief Financial Officer and Head of Corporate Development and Hy Levitsky, Juno’s Executive Vice President, Research and Chief Scientific Officer.
Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its clinical stage CD19 product candidates comprise JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies.
Pra Group Inc (NASDAQ:PRAA)’s shares gained 1.83% to $52.34.
PRA Group (PRAA), a global leader in acquiring non-performing loans, recently declared that its partner, Portfolio Recovery Associates, LLC (“PRA”), has reached a settlement with the Consumer Financial Protection Bureau (“CFPB”), successfully negotiating a contract that will not materially impact operations and will allow the company to focus on future opportunities without distraction and avoid costly and time-consuming litigation.
Steve Fredrickson, chairman and chief executive officer of PRA Group, Inc., said, “It was time to end this drawn out process and eliminate the threat of litigation, so we can focus with renewed vigor on serving our customers and growing our business. Given the circumstances, we went the extra mile to achieve closure, despite our objection to the CFPB’s characterization of PRA’s business practices.
PRA Group, Inc., a financial and business service company, engages in the purchase, collection, and administration of portfolios of defaulted consumer receivables in North America and Europe. It is involved in the acquisition, collection, and processing of unpaid and normal-course accounts receivable owed to credit grantors, governments, retailers, and others. The company also acquires receivables of Visa and MasterCard credit cards, private label and other credit cards, installment loans, lines of credit, insolvency accounts, deficiency balances of various types, legal judgments, and trade payables from various receivable owners, counting banks, credit unions, consumer finance companies, telecommunication providers, retailers, utilities, auto finance companies, student loan companies, and other debt buyers.
At the end of Wednesday’s trade, Hudson Pacific Properties Inc (NYSE:HPP)‘s shares dipped -1.28% to $27.73.
Hudson Pacific Properties, Inc. (HPP) declared that the company’s Board of Directors has declared a quarterly dividend on its common stock of $0.125 per share for the third quarter of 2015. The dividend will be paid on September 30, 2015 to stockholders of record on September 20, 2015.
In addition, the Board of Directors also declared a dividend for the third quarter of 2015 on its 8.375% Series B Cumulative Preferred Stock of $0.52344 per share. The dividend will be paid on September 30, 2015 to stockholders of record on September 20, 2015.
Hudson Pacific Properties, Inc. operates as a vertically integrated real estate trust (REIT) in the United States. It engages in owning, operating, and acquiring office, and media and entertainment properties primarily in Northern and Southern California in Los Angeles, Orange County, San Diego, San Francisco, Silicon Valley, and the East Bay. As of March 31, 2011, it owned a portfolio of 15 office properties; and 2 media and entertainment properties in California comprising about 4.4 million square feet.
TASER International, Inc. (NASDAQ:TASR), ended its Wednesday’s trading session with -2.14% loss, and closed at $X23.76XX.
TASER International (NASDAQ: TASR), which makes communities safer with innovative public safety technologies, declared that it has received notice from the United States Patent and Trademark Office (USPTO) that the USPTO has rejected all 20 claims of U.S. Patent 8,781,292 which has been assigned to Digital Ally, Inc. (the “Digital Ally” patent”). This USPTO office action is in response to an ex parte reexamination request filed by TASER. Digital Ally has until October 17, 2015 to file a response with the USPTO.
The Digital Ally patent describes an apparatus to detect when a video recorder has begun recording and to communicate with any recording device in range indicating that the recording device should start recording. The Digital Ally patent claims were found unpatentable by the USPTO due to preceding art found by TASER.
TASER International, Inc. develops, manufactures, and sells conducted electrical weapons (CEWs) worldwide. It operates through two segments, TASER Weapons and AXON. The company’s CEW products transmit electrical pulses along the wires and into the body affecting the sensory and motor functions of the peripheral nervous system. It offers three hand-held CEW product lines, counting TASER X26P and TASER X2, which integrates with EVIDENCE.com; and TASER X26.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
